AXIM Biotechnologies, Inc. (AXIM Biotech), a major investment of Medical Marijuana, Inc. (OTC: MJNA), recently partnered with Israel-based contract research organization (CRO). The partnership will begin with a proof of concept (POC) study using cannabidiol (CBD) and Gabapentin chewing gum to treat restless leg syndrome (RLS).
“We are proud to support AXIM Biotech as the company continues to identify new clinical applications for its proprietary chewing gum product,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.
RLS is also sometimes referred to as Willis-Ekbom Disorder (WED) and currently affects anywhere from 3-14.3% of Americans. The condition is associated with nocturnal spasms in the lower region of the body. These spasms can cause severe sleep loss and also chronic pain. This is a condition that can dampen a patient’s quality of life (QoL) by causing daytime lethargy, decreased immune function, higher stress, strained mood, and an overall decrease in general health.
Many of us are familiar with CBD as a treatment for epilepsy, but what is this other drug in the gum? Gabapentin is often used alongside other medications to help reduce seizures. It can also be valuable in reducing nerve pain when it is a symptom of shingles. Though these side effects aren’t true for every patient, Gabapentin has been known to cause drowsiness, dizziness, loss of coordination, tiredness, blurred/double vision, unusual eye movements, shaking/tremors, and/or swelling of the hands and feet.
The chewing gum uses a combination of CBD and Gabapentin and is currently Phase 2 of this single-center, double blind, randomized trial will explore the efficacy of the AXIM chewing gum on around 30 participants who are currently struggling with RLS.
Titus continued, ““Research shows that RLS may be related to abnormalities in the nervous system… We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders.”